Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Dapagliflozin (Item No. 11574) is a selective sodium-glucose cotransporter (SGLT) inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM; EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM).1,2 It improves glucose tolerance in normal rats and reduces hyperglycemia in Zucker diabetic fatty rats.3fluoro-Dapagliflozin is an analog of dapagliflozin that displays similar selectivity for inhibiting SGLT2 over SGLT1 (Kis = 5.3 and 330 nM, respectively).1 fluoro-Dapagliflozin (10 nM) significantly reduces phlorizin-sensitive sugar transport in COS-1 cells expressing human SGLT2.1
WARNING This product is not for human or veterinary use.
1. Structural selectivity of human SGLT inhibitors. Am. J. Physiol. Cell Physiol. 302(2), C373-C382 (2012).
2. SGLT2 inhibition -
3. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57(6), 1723-1729 (2008).